Skip to contentpdufa.bio

MAR002

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

MAR002 is a LISATA THERAPEUTICS, INC. program in acromegaly. Its next catalyst is a Readout in Q4 2027.

LSTA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: acromegaly. Sponsor: LISATA THERAPEUTICS, INC. (LSTA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027LSTA

Questions

When is MAR002's next FDA decision or readout?

The next tracked catalyst for MAR002 is a Readout in Q4 2027.

What happened at MAR002's most recent FDA decision?

No FDA decision for MAR002 is in our archive yet.

What is MAR002 used for?

In our records MAR002 is under review or in development for acromegaly.

Who makes MAR002?

LISATA THERAPEUTICS, INC. (LSTA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.